ABUS Should I Buy
Arbutus Biopharma Corp (ABUS) is not recommended as a strong buy for beginner, long-term investors due to a lack of clear positive momentum, absence of significant trading signals, and unimpressive financial performance. While the company boasts strong liquidity and a significant Q4 2025 revenue increase, it faces challenges with declining net income and EPS, and an ongoing patent dispute with Moderna. Analysts from Jefferies maintain a Buy rating but acknowledge the complexities of the patent case.
Arbutus: Q4 Earnings Snapshot
Arbutus Biopharma Corp. (ABUS) reported a Q4 loss of $3.8 million, or 1 cent per share, on revenue of $1.1 million. For the entire year, the company's loss narrowed to $33.5 million, with revenues reaching $14.1 million. Arbutus shares closed at $4.24, an increase from $3.28 a year prior.
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation announced its Q4 and full-year 2025 financial results, highlighting a strong financial position with $91.5 million in cash, cash equivalents, and marketable securities. The company reported a significant settlement with Moderna for $2.25 billion regarding LNP delivery technology infringement, including a $950 million upfront payment, and noted that two additional patients in its Phase 2a clinical trials for imdusiran achieved functional cure for chronic hepatitis B. Arbutus is also evaluating a return of capital to shareholders in Q3 2026 following the Moderna settlement payment.
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives
Arbutus Biopharma (ABUS) reported a mixed Q3 2025 with a loss of US$0.04 EPS and US$0.5 million in revenue, despite narrowing trailing twelve-month losses. The company's high P/B multiple of 11x compared to the biotech average of 2.5x is scrutinized, especially given its unprofitability. The article highlights the volatility of quarterly results and questions the sustainability of its brief Q2 profitability.
Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue Growth - News and Statistics
Arbutus Biopharma (ABUS) reported its financial results for Q4 and the full year 2025. The company posted a quarterly loss of $3.8 million and a full-year loss of $33.5 million, marking a reduction in its annual financial loss. Annual revenue reached $14.1 million, and the stock price was $4.24 per share, an increase from the previous year.
Arbutus: Fourth Quarter Financial Results Overview
Arbutus Biopharma Corp. reported a net loss of $3.8 million for the fourth quarter, or $0.01 per share, with revenues of $1.1 million. For the full year, the company reduced its annual loss to $33.5 million, or $0.17 per share, on total revenue of $14.1 million. The company's stock was trading at $4.24, an increase from $3.28 a year prior.
Arbutus: Fourth Quarter Financial Results Overview
Arbutus Biopharma Corp. reported a net loss of $3.8 million for the fourth quarter, or $0.01 per share, with revenues totaling $1.1 million. For the full year, the company reduced its loss to $33.5 million ($0.17 per share) and generated $14.1 million in revenue. The stock was $4.24 at the close, an increase from $3.28 the previous year.
Arbutus Biopharma Corp expected to post a loss of 4 cents a share - Earnings Preview
Arbutus Biopharma Corp (ABUS) is projected to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The article provides financial news regarding the company's expected performance.
Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results
Arbutus Biopharma (NASDAQ:ABUS) reported better-than-expected earnings for the quarter, with EPS of ($0.01) against an estimated ($0.06) and revenue of $1.05 million against $0.83 million. Despite beating estimates, the company remains unprofitable and its shares slipped approximately 3% after the announcement. Analysts currently rate the stock as "Hold" with a consensus price target of $5.00.
Arbutus: Q4 Earnings Snapshot
Arbutus Biopharma Corp. (ABUS) reported a fourth-quarter loss of $3.8 million, or 1 cent per share, on revenues of $1.1 million. For the full year, the company's loss narrowed to $33.5 million, or 17 cents per share, with revenues totaling $14.1 million. The article also notes the company's stock closed at $4.24, an increase from $3.28 a year prior.
Arbutus: Q4 Earnings Snapshot
Arbutus Biopharma Corp. reported a loss of $3.8 million, or 1 cent per share, in its fourth quarter, with revenue of $1.1 million. For the full year, the company narrowed its loss to $33.5 million, or 17 cents per share, on revenue of $14.1 million. The company's shares closed at $4.24, an increase from $3.28 a year ago.
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure
Arbutus Biopharma Corp. experienced a significant stock decline of 8.47%, reaching an intraday low of $4.21, contrasting with the overall market. Despite this, the company has shown resilience over the past month and year, with strong institutional ownership. Its market capitalization stands at USD 821 million within the Pharmaceuticals & Biotechnology sector.
Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Arbutus Biopharma Corp., a small-cap biotechnology company, has revised its stock evaluation amid current market dynamics, with its stock priced at $4.70. Despite a slight dip from its previous close, the company has delivered a 35.84% return over the past year, outperforming the S&P 500. Technical indicators show mixed signals, but the stock has demonstrated resilience, particularly with a 28.07% return last month, highlighting its ability to navigate market fluctuations.
Here's Arbutus Biopharma's share of $950M Moderna settlement
Arbutus Biopharma is set to receive $190 million from a $950 million settlement with Moderna, resolving a patent infringement lawsuit related to Moderna's Covid-19 vaccine, Spikevax. The Bucks County-based company, along with Genevant, is also involved in ongoing patent infringement lawsuits against Pfizer and BioNTech. The settlement was announced on March 3, 2026.
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna (MRNA) has settled a patent dispute with Genevant Sciences (a subsidiary of Roivant Sciences ROIV) and Arbutus Biopharma (ABUS) for $2.25 billion, resolving claims of unauthorized use of LNP technology in its COVID-19 and RSV vaccines. The agreement involves an upfront payment of $950 million, with a potential additional $1.3 billion if Moderna loses a federal appeal. This settlement led to Moderna's stock gaining nearly 6% in after-market trading and is expected to result in a $950 million charge in Q1 2026, though the company projects strong liquidity by year-end.
Moderna to pay about US$1 bil to settle Arbutus litigation
Moderna has agreed to pay US$950 million to settle all worldwide litigation with Arbutus Biopharma Corp and Genevant Sciences GmbH, resolving patent infringement claims related to the lipid nanoparticle technology used in its Covid-19 vaccine. This settlement removes a significant financial risk for Moderna, which had struggled to launch new products after the initial success of its vaccine. While Moderna's shares rose, Arbutus's fell, indicating investor disappointment regarding potential future payouts.
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement
Moderna has agreed to a global settlement with Genevant Sciences and Arbutus Biopharma, totaling up to $2.25 billion, to resolve patent infringement claims related to its COVID-19 vaccine, Spikevax. The dispute concerned Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology. The settlement includes an upfront payment of $950 million in July 2026 and an additional $1.3 billion contingent on an appellate ruling regarding a specific legal statute.
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna
Arbutus Biopharma and Genevant Sciences have reached a $2.25 billion global settlement with Moderna to resolve all LNP patent disputes related to Moderna's COVID-19 vaccines, including Spikevax. Moderna will make an upfront payment of $950 million and potentially an additional $1.3 billion, securing a non-exclusive license for SM-102 LNP vaccine technology. This agreement is described as transformative for Arbutus, which is considering a return of capital to shareholders, while separate litigation against Pfizer/BioNTech continues.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Settlement with Moderna Over LNP Technology Patent Infringement
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion settlement with Moderna regarding patent infringement over the unauthorized use of Genevant's LNP delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million due in July 2026 and an additional contingent payment of $1.3 billion depending on the outcome of Moderna's appeal concerning Section 1498. This agreement, which establishes the validity of Genevant/Arbutus patents and grants Moderna a non-exclusive license, resolves all related U.S. and international litigation.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Settlement with Moderna Over LNP Technology Patent Infringement
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion settlement with Moderna regarding patent infringement over the unauthorized use of Genevant's lipid nanoparticle (LNP) delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million and a contingent payment of $1.3 billion, pending the outcome of Moderna's appeal concerning Section 1498. This agreement grants Moderna a global non-exclusive license for the LNP technology for infectious disease applications and resolves all related litigation, while similar litigation against Pfizer/BioNTech is still ongoing.
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement
Arbutus Biopharma and Genevant Sciences have reached a global patent settlement with Moderna for up to $2.25 billion, resolving all litigation related to lipid nanoparticle (LNP) technology. The settlement includes an upfront payment of $950 million by July 2026 and a contingent payment of $1.3 billion based on the outcome of Moderna’s Section 1498 appeal. Arbutus is entitled to 20% of the settlement proceeds after litigation costs and is evaluating a potential return of capital to shareholders.
$2.25 billion Moderna deal ends COVID vaccine patent fight
Arbutus Biopharma and Genevant Sciences announced a $2.25 billion global settlement with Moderna over the unauthorized use of their LNP delivery technology in COVID-19 vaccines. The settlement includes an upfront payment of $950 million in July 2026 and a contingent $1.3 billion payment tied to an appellate ruling on Section 1498. As part of the agreement, Moderna receives a global non-exclusive license to the LNP technology for infectious disease applications, effectively ending the patent infringement litigation against Moderna.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna over the unauthorized use of their LNP delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million and a contingent payment of $1.3 billion. Arbutus Biopharma is evaluating a return of capital to shareholders in Q3 2026, and Roivant will host an investor call to discuss the updates.
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case
A Delaware federal court has issued a ruling in the patent dispute between Arbutus Biopharma and Moderna regarding lipid nanoparticle technology. The court significantly narrowed Moderna's defenses by barring obviousness and derivation arguments due to prior inter partes review estoppel and issue preclusion. However, Moderna's enablement defense, supported by expert testimony, will proceed to a jury trial, leaving final patent validity unresolved.
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury
Arbutus Biopharma has achieved a partial summary judgment against Moderna, barring Moderna's obviousness and derivation defenses related to certain patents. While the court ruled in Arbutus's favor on several points including IPR estoppel and issue preclusion, the dispute regarding enablement will proceed to a jury for resolution. This legal development stems from an SEC filing by Arbutus Biopharma Corp (ABUS).
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Genevant Sciences and Arbutus Biopharma have initiated international patent infringement lawsuits against Moderna in 30 countries, alleging that Moderna's mRNA vaccines infringe on their lipid nanoparticle (LNP) technology patents. These new global actions expand upon existing U.S. litigation, with a jury trial scheduled for September 2025 in Delaware. The legal battles highlight the critical role of LNP technology in mRNA vaccines and could result in significant monetary relief and injunctions against Moderna.
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened
Arbutus Biopharma (NASDAQ:ABUS) stock briefly traded above its 200-day moving average of $4.28, hitting an intraday high of $4.34 before closing at $4.17. The company has a market capitalization of approximately $802 million and institutional investors hold about 43.8% of its shares. Analyst ratings are mixed, leading to an average "Hold" consensus and a $5.00 price target.
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O
The European Patent Office has invalidated a key Arbutus Biopharma patent, which benefits Moderna by reducing potential legal challenges in Europe. Arbutus Biopharma, a clinical-stage biopharmaceutical company focused on chronic hepatitis B, faces financial challenges including negative revenue growth and profitability. Despite strong financial strength metrics, investors are advised to consider the company's ongoing patent disputes and sector-specific risks.
ABUS Stock Tumbles on European Patent Revocation
Arbutus Biopharma Corporation's (ABUS) stock fell by 14.04% following the European Patent Office's revocation of a crucial patent, a decision influenced by challenges from Moderna and Merck. This legal setback exacerbates the company's existing financial struggles, which include negative profit margins and a high price-to-sales ratio. Analysts maintain a negative sentiment, citing significant vulnerabilities for ABUS in the competitive biotech landscape.
Market Dynamics Cause Shifts for Arbutus Biopharma
Arbutus Biopharma (ABUS) stock has experienced an 11.05% decline amidst market uncertainty regarding strategic shifts and challenges. Despite financial hurdles, the company shows promise through innovative pursuits, strong partnerships, and controlled debt, aiming for wider global reach. Investors remain cautiously optimistic, focusing on risk management and monitoring economic indicators to navigate competitive pressures and ensure sustainable growth.
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash
Arbutus Biopharma (ABUS) experienced an 18% stock crash after the European Patent Office revoked its EP 2279254 patent on January 15. Despite this, Arbutus plans to appeal the decision and asserts it will not impact ongoing patent infringement cases against Moderna in other regions. While Moderna's stock rose, and Merck's fell, retail sentiment on Stocktwits saw the ABUS dip as a buying opportunity, indicating mixed views on its future.
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Here's Why
Arbutus Biopharma (NASDAQ:ABUS) shares gapped down by about 12.9% on Friday, opening at $3.94 after a $4.70 close, with roughly 3.12 million shares traded. The company has a consensus "Hold" rating from analysts with a $5.00 target, despite recent mixed analyst actions including a "Buy" call from Chardan and a downgrade to "Hold" from Wall Street Zen. This decline follows a quarterly earnings report that beat EPS expectations but missed on revenue, with the company remaining unprofitable.
European Patent Office revokes Arbutus Biopharma patent following appeal
The European Patent Office's Board of Appeal has revoked Arbutus Biopharma Corporation's European patent EP 2279254, a decision the company disagrees with and plans to challenge. Despite this, Arbutus does not anticipate the revocation to impact its ongoing patent infringement cases against Moderna, Pfizer, and BioNTech in other jurisdictions like the U.S., Japan, and Canada, citing that the ruling was based on "added matter" which is not applicable there. The company maintains a strong liquidity position, as indicated by InvestingPro data, and has recently reported encouraging clinical data for its hepatitis B treatment despite a third-quarter loss.
Arbutus Biopharma Corp - EPO revokes Arbutus Biopharma's European patent EP 2279254 - SEC filing
The European Patent Office (EPO) has revoked Arbutus Biopharma's European patent EP 2279254, as disclosed in an SEC filing. This development is significant for Arbutus Biopharma, a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B virus (cHBV) infection. The company's pipeline includes Imdusiran and AB-101.
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp
The Hepatitis B market is projected to experience significant growth by 2034, driven by increasing prevalence and developing pipeline products. Several key companies are advancing therapies, with Precision BioSciences, Barinthus Biotherapeutics, and YS Biopharma reporting significant clinical trial progress. The report highlights market opportunities in new diagnostic tools and research into conventional therapeutic methods.
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826
David Hastings, the CFO of Arbutus Biopharma (NASDAQ: ABUS), recently sold 34,705 shares of the company's stock at an average price of $2.10 per share, totaling $72,826. This transaction follows other insider selling activities at the company over the past year.
Pharma Patent Trials Loom in 2026 for Wegovy, Covid-Vaccine Tech
Siegmund Gutman, Life Science Litigation Practice Chair at Mintz, was quoted in a Bloomberg Law article discussing major pharmaceutical patent lawsuits scheduled for trial in 2026. He commented on the "huge case" involving Arbutus Biopharma Corp. and Genevant Sciences GmbH seeking royalties from Moderna Inc.'s Spikevax Covid-19 vaccine, highlighting it as a test for older patents against modern validity scrutiny for blockbuster drugs.
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Arbutus Biopharma (NASDAQ:ABUS) recently saw its stock price climb above its 200-day moving average, reaching $4.68 with a high of $4.80. Despite this technical strength, analysts remain mixed, with a consensus "Hold" rating and an average price target of $5.00. The company faces fundamental challenges, including a negative net margin and a miss on revenue expectations, despite beating EPS estimates last quarter.
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS
BlackBarn Capital Partners LP significantly increased its stake in Arbutus Biopharma Corporation by 11.2% during the second quarter, making it their 15th largest holding with 2.6 million shares valued at $8.045 million. Other institutional investors like Bank of America Corp DE and Adage Capital Partners GP L.L.C. also boosted their holdings. Despite this, analysts have a "Hold" consensus rating for Arbutus Biopharma, with a target price of $5.00.
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation
Arbutus Biopharma Corp (ABUS) provided an update on its patent litigation against Moderna, Pfizer, and BioNTech, asserting infringement on its LNP patents. A U.S. jury trial against Moderna is set for March 2026, with ex-U.S. Moderna cases expected to begin in 2026, and Pfizer/BioNTech litigation awaiting scheduling. The company notes generally favorable Markman rulings in its U.S. cases.
Arbutus Biopharma shares rise as imdusiran data shows promising results
Arbutus Biopharma (NASDAQ:ABUS) shares rose 5% in after-hours trading despite missing Q3 analyst estimates, driven by promising clinical data for its hepatitis B treatment, imdusiran. The data showed 46% of Phase 2a patients could discontinue treatment, with 94% remaining off for over two years, and all HBV DNA positive patients in Phase 1b achieving undetectable levels after 18 weeks. The company also highlighted its strong financial position and ongoing patent litigation against Moderna and Pfizer/BioNTech.
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital
Chardan Capital has reaffirmed a "Buy" rating for Arbutus Biopharma (NASDAQ:ABUS) with a $5.00 price target, suggesting a 10.62% upside from its current price. Despite beating EPS estimates, the biopharmaceutical company reported lower-than-expected revenue and remains unprofitable. Several institutional investors have significantly increased their stakes in the company, which currently holds a "Hold" consensus rating from MarketBeat with a $5.00 target price.
Arbutus Biopharma Faces Losses And Legal Battles This Quarter
Arbutus Biopharma reported a significant net loss and lower-than-expected revenue this quarter, alongside challenges in its Phase 2a imdusiran trial. Despite these setbacks, the company is prioritizing key drugs, trimming R&D, and continues to engage in high-stakes patent lawsuits, including recent wins against Pfizer and BioNTech. Wall Street maintains a cautious 'buy' outlook, indicating optimism about Arbutus's ability to manage its financial and legal pressures.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its third-quarter 2025 financial results, highlighting a strong financial position with $93.7 million in cash. The company provided an update on its imdusiran clinical data, showing that 46% of Phase 2a patients discontinued treatment, with 94% remaining off treatment for up to two years. Arbutus also detailed its ongoing LNP litigation against Moderna and Pfizer/BioNTech, with key trial dates scheduled for 2026 and 2027.
Arbutus Biopharma earnings missed, revenue fell short of estimates
Arbutus Biopharma (NASDAQ: ABUS) reported third-quarter EPS of $-0.040, missing analyst estimates of $-0.033, and revenue of $529K, which fell short of the consensus estimate of $1.39M. Despite the missed earnings and revenue, Arbutus Biopharma's stock has seen a significant increase over the past 3 and 12 months. The company's financial health is rated as "fair performance" by InvestingPro.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its third-quarter 2025 financial results, highlighting a strong financial position with $93.7 million in cash and investments. The company provided an update on its LNP litigation against Moderna and Pfizer/BioNTech, with significant trial dates scheduled. Additionally, Arbutus shared positive clinical data for its lead hepatitis B therapeutic, imdusiran (AB-729), showing that 46% of Phase 2a patients were able to discontinue all treatment and 94% of long-term follow-up patients remain off treatment for up to two years.
Arbutus Biopharma appoints new CEO and reshapes board
Arbutus Biopharma (NASDAQ: ABUS) has appointed Lindsay Androski as its new CEO and a board member, effective immediately. The company also announced a significant overhaul of its board, with four new directors joining and previous members departing, reducing the board to five members. These changes aim to refocus on advancing the company's pipeline and leveraging its LNP delivery technology through Genevant, with a temporary halt in investor meetings for strategic review.
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 and Revenue of $10.7M, Surpassing Estimates
Arbutus Biopharma Corp reported strong Q2 2025 earnings, with EPS of $0.01 and revenue of $10.7 million, significantly exceeding analyst estimates due to deferred revenue recognition from reacquired rights to imdusiran. The company achieved a net income of $2.5 million, a substantial improvement from a loss in the prior year, and maintained a strong cash position while reducing operating expenses. Despite ongoing litigation, strategic developments and financial improvements highlight a positive outlook.
Lindsay Androski named CEO of Arbutus
Arbutus Biopharma Corp. appointed Lindsay Androski as CEO and replaced its entire board of directors. Androski, previously with Genevant Sciences Corp. and Roivant Sciences Ltd., will lead the company in reviewing its HBV development plans and strategic options. The new board also comprises Robert Beardsley, Anuj Hasija, Matthew Gline, Joseph Bishop, and Androski.
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum
Arbutus Biopharma (NASDAQ:ABUS) is highlighted for its strong technical and fundamental momentum, aligning with Mark Minervini's Trend Template and high-growth criteria. The stock exhibits solid technical traits, trading above key moving averages with high relative strength, and shows significant fundamental improvements in EPS and sales growth. These factors suggest a potential for continued price gains, supported by both market position and financial performance.
